Torin 1

Catalog No.S2827

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

5 Customer Reviews

Huh-7.5 cells were treated with increasing concentration of Torin 1, a known autophagy inducer, and the autophagy response was assessed by measuring LC3II and p62 levels.

Am J Pathol 2014 184(1), 214-29. Torin 1 purchased from Selleck.

Flag-tagged SENP3 was immunoprecipitated from HeLa cells and used for in vitro phosphorylation assay with [32P]ATP with either the mock-treated or Torin1-treated mTOR/Raptor/MLST8 complex. (Upper) The samples then were subjected to SDS-PAGE, followed by autoradiography. mTOR autophosphorylation is indicated by an asterisk. (Lower) Immunopurified SENP3 was monitored by Western blotting with anti-Flag antibody.

Mol Cell Biol 2014 34(24), 4474-84. Torin 1 purchased from Selleck.
Exp Cell Res, 2018, 363(1):84-94. Torin 1 purchased from Selleck.

Representative Western blots showing LC3 in PP242 (PP) or Torin1 (Tor) treated HepG2 cells. HepG2 cells were treated with 10 uM PP242 or 0.1 uM Torin1 for 24 h.

Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.05.047. Torin 1 purchased from Selleck.
Bone marrow derived macrophages were pre-treated with 10nM Torin 1 for 1h prior to LPS treatment (100 ng/ml). TNF-a production was analyzed 24h later.

Lim Hsiu Kim, Lina from National University of Singapore. Torin 1 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	NGXwe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXkTWM2OD1yLkCwNFMxPiEQvF2=	M1[yNXNCVkeHUh?=
OCUB-M	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\6TWM2OD1yLkCwNVk1KM7:TR?=	M4fHcXNCVkeHUh?=
DOHH-2	M4LXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFK5UHFKSzVyPUCuNFAzOjVizszN	NG\SSVBUSU6JRWK=
NOS-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEG2O2dKSzVyPUCuNFAzPDJizszN	M1v3RXNCVkeHUh?=
L-363	NF:3R5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLEUlRKSzVyPUCuNFAzQDRizszN	MXjTRW5ITVJ?
RL95-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMECzNkDPxE1?	NGXQdVFUSU6JRWK=
BL-70	M4n0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDUTWM2OD1yLkCwN\|M4KM7:TR?=	MlHKV2FPT0WU
TGBC1TKB	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGP4RotKSzVyPUCuNFA{PzlizszN	NYjpc3FYW0GQR1XS
697	NIL0XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMEC2N\|Qh\|ryP	M{DnW3NCVkeHUh?=
RPMI-8226	NV;5[ZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj0TWM2OD1yLkCwOlUyKM7:TR?=	MkPkV2FPT0WU
BL-41	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMEC2PVYh\|ryP	M{fBW3NCVkeHUh?=
MRK-nu-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMEC3NFch\|ryP	NVvQUYdkW0GQR1XS
EW-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlj6TWM2OD1yLkCwO\|Q6KM7:TR?=	NWnYNooxW0GQR1XS
EVSA-T	NH\lc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDvTWM2OD1yLkCwPFkzKM7:TR?=	Ml3CV2FPT0WU
HUTU-80	M3jvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\YR4FvUUN3ME2wMlAxQTJ7IN88US=>	NVyz[XJlW0GQR1XS
VA-ES-BJ	NEHzNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTtWXRsUUN3ME2wMlAxQTh2IN88US=>	Moj6V2FPT0WU
GCIY	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvNTWM2OD1yLkCxNFA4KM7:TR?=	MmT2V2FPT0WU
ES6	NXrueGZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nBSGlEPTB;MD6wNVA5OyEQvF2=	M2LQ[3NCVkeHUh?=
NALM-6	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1iyd2lEPTB;MD6wNVExOiEQvF2=	M1rPV3NCVkeHUh?=
LB996-RCC	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTuTWM2OD1yLkCxNVM4KM7:TR?=	NU\mbXp1W0GQR1XS
EW-16	NIj0[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvkTWM2OD1yLkCxNVkzKM7:TR?=	NUPqUXhjW0GQR1XS
KALS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vlfGlEPTB;MD6wNVE6QCEQvF2=	MmHIV2FPT0WU
OPM-2	M1vnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELF[pVKSzVyPUCuNFEzQSEQvF2=	M1LWXXNCVkeHUh?=
KU812	M3HQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEKxR2VKSzVyPUCuNFEzQTZizszN	MnTLV2FPT0WU
A4-Fuk	M3KxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLUNZVKSzVyPUCuNFE{OTlizszN	NETFVmxUSU6JRWK=
KGN	NEnMOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nDdWlEPTB;MD6wNVM2QSEQvF2=	NUjyc4hkW0GQR1XS
KS-1	NFXES\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu0TWM2OD1yLkCxN\|kzKM7:TR?=	NXfqOHdzW0GQR1XS
no-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHm2OnpKSzVyPUCuNFE{QTVizszN	M33DenNCVkeHUh?=
PSN1	NHjzNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWCyWoxyUUN3ME2wMlAyPDB7IN88US=>	M3vhO3NCVkeHUh?=
SK-LMS-1	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXHZ45pUUN3ME2wMlAyPDF\|IN88US=>	M{LVNHNCVkeHUh?=
LS-411N	MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEG0N\|kh\|ryP	NHfJZVNUSU6JRWK=
HT-144	NXKxRZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXxRo5tUUN3ME2wMlAyPDVzIN88US=>	M3f1cnNCVkeHUh?=
ACN	NVHyZmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMEG1JO69VQ>?	MVPTRW5ITVJ?
RKO	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fyOmlEPTB;MD6wNVU{OyEQvF2=	NGHQSVNUSU6JRWK=
CMK	NHzBbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMEG1OFMh\|ryP	NHXQfYpUSU6JRWK=
GB-1	NGrn[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DSZmlEPTB;MD6wNVU2OyEQvF2=	MWrTRW5ITVJ?
KE-37	M1z2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXJTWM2OD1yLkCxOVc{KM7:TR?=	NIrNdm5USU6JRWK=
no-10	NVj6[mxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XGT2lEPTB;MD6wNVU5PCEQvF2=	MV7TRW5ITVJ?
MOLT-16	NFz2Z4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMEG2NlIh\|ryP	NYfWVYVtW0GQR1XS
HEL	NHL0NplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTzW3RKSzVyPUCuNFE3PCEQvF2=	MXvTRW5ITVJ?
NCI-H1355	M4TkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4G3fmlEPTB;MD6wNVY1PiEQvF2=	M4LLN3NCVkeHUh?=
IST-MEL1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2H3WmlEPTB;MD6wNVc4PCEQvF2=	M4K3bnNCVkeHUh?=
MHH-PREB-1	M1ewN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMEG4NVgh\|ryP	M3nmN3NCVkeHUh?=
ES8	NGfUOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\CVWlsUUN3ME2wMlAyQDR2IN88US=>	MVLTRW5ITVJ?
LC-2-ad	MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL2XpZUUUN3ME2wMlAzOTN5IN88US=>	NHm2e\|hUSU6JRWK=
LAMA-84	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEKxOlch\|ryP	M4H2VnNCVkeHUh?=
BV-173	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHvWlFKSzVyPUCuNFIzODNizszN	MVPTRW5ITVJ?
SW872	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjQN5VKSzVyPUCuNFIzPDdizszN	NYXIWGJLW0GQR1XS
SK-UT-1	NV:0SZlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1X6b2lEPTB;MD6wNlI3OSEQvF2=	M4PRfnNCVkeHUh?=
OS-RC-2	NITTZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTuVZNLUUN3ME2wMlAzOzJ\|IN88US=>	NYfJW3ptW0GQR1XS
NCI-H747	NUPKTIpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzCS\|NKSzVyPUCuNFI{OyEQvF2=	MoDoV2FPT0WU
MZ2-MEL	M37jUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vIT2lEPTB;MD6wNlM{PyEQvF2=	MkXKV2FPT0WU
TE-11	NV7XVHJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrwTFg2UUN3ME2wMlAzOzd{IN88US=>	NHnmUllUSU6JRWK=
KURAMOCHI	NE\QUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLGTWM2OD1yLkCyOFE1KM7:TR?=	MnXtV2FPT0WU
HD-MY-Z	NIOxWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMEK0NlYh\|ryP	M2fQ[XNCVkeHUh?=
GI-1	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEK0Olkh\|ryP	NFLRZ\|BUSU6JRWK=
LB1047-RCC	NEntdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEK0PFgh\|ryP	MljjV2FPT0WU
TE-12	M{LwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MniyTWM2OD1yLkCyOVUh\|ryP	NYDOV3dLW0GQR1XS
MZ7-mel	M3e5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMEK2NFkh\|ryP	MWTTRW5ITVJ?
MMAC-SF	M{jPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnUZ5d7UUN3ME2wMlAzPjN\|IN88US=>	MkfXV2FPT0WU
A101D	M3fMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX35eINTUUN3ME2wMlAzPjVizszN	MV;TRW5ITVJ?
GR-ST	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zQc2lEPTB;MD6wNlY2PSEQvF2=	M4jSUnNCVkeHUh?=
MC116	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XZXmlEPTB;MD6wNlY5KM7:TR?=	NInVVZZUSU6JRWK=
Ramos-2G6-4C10	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHMNZBMUUN3ME2wMlAzPzVizszN	NEXpcZJUSU6JRWK=
ATN-1	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Kw[mlEPTB;MD6wNlc5QSEQvF2=	MUTTRW5ITVJ?
MFH-ino	NHu3cY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlntTWM2OD1yLkCyPFEzKM7:TR?=	NWKzdI1nW0GQR1XS
DEL	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTSTWM2OD1yLkCyPFE2KM7:TR?=	NHzDcIVUSU6JRWK=
OCI-AML2	NGD3PI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjFR5Y{UUN3ME2wMlAzQDdzIN88US=>	MoXKV2FPT0WU
LXF-289	NH3DbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\RVJZKSzVyPUCuNFI5PzJizszN	NV[2dnE3W0GQR1XS
IA-LM	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHyyRo1KSzVyPUCuNFI6OTdizszN	M4TaZ3NCVkeHUh?=
EoL-1-cell	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PV[2lEPTB;MD6wNlk6PiEQvF2=	M4fLXnNCVkeHUh?=
OVCAR-4	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LTXWlEPTB;MD6wN\|A6PCEQvF2=	NVfEUohsW0GQR1XS
ES1	NFj0UYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHu4SIhKSzVyPUCuNFMxQTdizszN	MWLTRW5ITVJ?
CESS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlezTWM2OD1yLkCzNFk6KM7:TR?=	MYfTRW5ITVJ?
GAK	MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7pfJAyUUN3ME2wMlA{OTh4IN88US=>	MWfTRW5ITVJ?
NTERA-S-cl-D1	M2rjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEOyNlYh\|ryP	NHjXdGJUSU6JRWK=
TE-10	M2fKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XoOWlEPTB;MD6wN\|MyOSEQvF2=	MYrTRW5ITVJ?
CCRF-CEM	NVXvRZRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\JdmJXUUN3ME2wMlA{OzdzIN88US=>	MXjTRW5ITVJ?
NMC-G1	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEO0OFgh\|ryP	MXTTRW5ITVJ?
HOP-62	M1LZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEO1OVYh\|ryP	M1jBWnNCVkeHUh?=
SH-4	M4W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jl[GlEPTB;MD6wN\|U5OiEQvF2=	NFfESmtUSU6JRWK=
NCI-H1648	M{L4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEO2NlIh\|ryP	NHfCbWNUSU6JRWK=
EB-3	M2P3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\HfmlEPTB;MD6wN\|Y1OyEQvF2=	M4n5fHNCVkeHUh?=
BB65-RCC	NXvu[VU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfCeZhKSzVyPUCuNFM3QTFizszN	MmXBV2FPT0WU
BE-13	MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\3U\|lKSzVyPUCuNFM4PTlizszN	M{GyUXNCVkeHUh?=
CP67-MEL	NGr4V3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfkXWlKUUN3ME2wMlA{PzV7IN88US=>	MlnZV2FPT0WU
SW954	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITldIpKSzVyPUCuNFM4QSEQvF2=	NYTOb\|JqW0GQR1XS
TE-5	M4i3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEO4OVQh\|ryP	NHz4[GdUSU6JRWK=
HCE-4	NH\RTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknTTWM2OD1yLkCzPFU2KM7:TR?=	NETDT\|BUSU6JRWK=
LC-1F	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEi4SoRKSzVyPUCuNFM6QDlizszN	Mk\DV2FPT0WU
TK10	NV:0WHdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HjdWlEPTB;MD6wOFAyQSEQvF2=	NGXIT5lUSU6JRWK=
SJSA-1	M1rSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvKbWRCUUN3ME2wMlA1OTh6IN88US=>	Mk\NV2FPT0WU
Daudi	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTv[HBqUUN3ME2wMlA1OjJ3IN88US=>	NUfOfZk{W0GQR1XS
SW982	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvvTWM2OD1yLkC0NlQ3KM7:TR?=	MWXTRW5ITVJ?
SF126	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMESzOlEh\|ryP	Mk\OV2FPT0WU
TE-15	NXHmdFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMES0N\|Uh\|ryP	M1HIXHNCVkeHUh?=
COLO-684	NH7pO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXJVXB3UUN3ME2wMlA1PTZzIN88US=>	NYDaN\|lXW0GQR1XS
8-MG-BA	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMES2Nlkh\|ryP	MXfTRW5ITVJ?
NB13	NECy[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TMWWlEPTB;MD6wOFc4PiEQvF2=	NFTlS\|lUSU6JRWK=
HCC1599	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknNTWM2OD1yLkC0PFc6KM7:TR?=	MUnTRW5ITVJ?
SK-PN-DW	M1TFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXhTWM2OD1yLkC0PVQ6KM7:TR?=	M2P0OXNCVkeHUh?=
ALL-PO	NWjRS217T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPHUXRyUUN3ME2wMlA1QTV4IN88US=>	NHezWoJUSU6JRWK=
NB6	NWOxemtkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojLTWM2OD1yLkC1NlcyKM7:TR?=	NXPRSXJKW0GQR1XS
IST-SL2	M1P4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT4W5FXUUN3ME2wMlA2OzZ{IN88US=>	Mn36V2FPT0WU
BB30-HNC	NUfrVVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLNT3BFUUN3ME2wMlA2PzNizszN	MkD5V2FPT0WU
SW962	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1i5V2lEPTB;MD6wOVc3OyEQvF2=	NGDidphUSU6JRWK=
TGBC24TKB	NUH4XpN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jRSmlEPTB;MD6wOVc6QSEQvF2=	M3:xfXNCVkeHUh?=
KINGS-1	M2jrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPzbIpKSzVyPUCuNFU5ODNizszN	MXLTRW5ITVJ?
HC-1	NITs[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHWWlBVUUN3ME2wMlA2QDJ5IN88US=>	MlHsV2FPT0WU
RS4-11	NIDRNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFu0Nm9KSzVyPUCuNFU6OzhizszN	MWjTRW5ITVJ?
LS-123	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXUTWM2OD1yLkC1PVQzKM7:TR?=	NGTlWZhUSU6JRWK=
A3-KAW	NHLofGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqwTHNKSzVyPUCuNFYzOjVizszN	NVGxZocxW0GQR1XS
SNB75	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHft[XdKSzVyPUCuNFY{PDFizszN	NGSy[odUSU6JRWK=
SR	NYThTWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mle3TWM2OD1yLkC2N\|c1KM7:TR?=	MlHlV2FPT0WU
LOUCY	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\2TWlEPTB;MD6wOlM6PCEQvF2=	MoHxV2FPT0WU
K5	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXQTWM2OD1yLkC2OFA{KM7:TR?=	NWfMNoNmW0GQR1XS
Becker	NIDUTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nBVWlEPTB;MD6wOlQzKM7:TR?=	NWPmNJduW0GQR1XS
CTV-1	NWnOTY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf1TWM2OD1yLkC2OVQ5KM7:TR?=	M3;SUHNCVkeHUh?=
KLE	M3fOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3tTWM2OD1yLkC2OVg1KM7:TR?=	Moj2V2FPT0WU
MZ1-PC	NVrncJZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHKWnhKSzVyPUCuNFY2QThizszN	MXTTRW5ITVJ?
MOLT-4	NHn3W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHVZ3FLUUN3ME2wMlA3PjB3IN88US=>	Mn7yV2FPT0WU
MLMA	MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDJTWM2OD1yLkC2O\|gh\|ryP	NWDL[Wg4W0GQR1XS
A388	M{PSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fwdmlEPTB;MD6wOlg6OyEQvF2=	M1rLb3NCVkeHUh?=
MV-4-11	MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\PTotmUUN3ME2wMlA3QTl3IN88US=>	M1TpO3NCVkeHUh?=
DSH1	NGLkVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXpTWM2OD1yLkC3NVc{KM7:TR?=	M{\6[3NCVkeHUh?=
MONO-MAC-6	NEX0S\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIT6dVJKSzVyPUCuNFczOTJizszN	MkfDV2FPT0WU
ARH-77	NIjSUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjkTWM2OD1yLkC3Nlc5KM7:TR?=	NYGzfJM6W0GQR1XS
LB771-HNC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHhbG1KSzVyPUCuNFc2PDlizszN	MmnaV2FPT0WU
PF-382	NFHjWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFe0PI5KSzVyPUCuNFc2PjlizszN	MXHTRW5ITVJ?
KM12	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXK5V3NCUUN3ME2wMlA4PjRizszN	NF:zXFJUSU6JRWK=
HAL-01	M4niOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3q5[2lEPTB;MD6wO\|Y2QCEQvF2=	Mnz0V2FPT0WU
RPMI-8402	NHm5SIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIG5bppKSzVyPUCuNFc4QDlizszN	M1yzNXNCVkeHUh?=
OMC-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnDZVJlUUN3ME2wMlA4QDB2IN88US=>	M2jCSXNCVkeHUh?=
HT	NEjTPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMEig{txO	NHO3Z2hUSU6JRWK=
QIMR-WIL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fUemlEPTB;MD6wPFA2PSEQvF2=	M2PWU3NCVkeHUh?=
KNS-42	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2iwW2lEPTB;MD6wPFIxOyEQvF2=	MXLTRW5ITVJ?
BC-3	NXTzVYpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vicGlEPTB;MD6wPFIxPCEQvF2=	Ml\CV2FPT0WU
ES4	NVjGfXVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7EWGVUUUN3ME2wMlA5Ojl4IN88US=>	M1vZRnNCVkeHUh?=
NCI-H23	NYfo[3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTrOZpKSzVyPUCuNFg1PCEQvF2=	NEj1TpZUSU6JRWK=
LB2518-MEL	NXztdpM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLDT49SUUN3ME2wMlA5Pjl4IN88US=>	NHziZ2pUSU6JRWK=
LC4-1	NF3SSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXJTWM2OD1yLkC4O\|M5KM7:TR?=	NEmwOmpUSU6JRWK=
SIG-M5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWf5RmhGUUN3ME2wMlA5QTB2IN88US=>	NH\EOoRUSU6JRWK=
LP-1	NUD6cFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMEi5N\|gh\|ryP	NITJd5RUSU6JRWK=
TE-8	M{\vZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEmwNVYh\|ryP	Ml7jV2FPT0WU
K-562	MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvMTWM2OD1yLkC5NVIh\|ryP	NWriXngxW0GQR1XS
J-RT3-T3-5	NXPUenhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMEmxOVMh\|ryP	MULTRW5ITVJ?
DU-4475	M3zTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoP2TWM2OD1yLkC5NVY2KM7:TR?=	MXvTRW5ITVJ?
RXF393	NVrvN4dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDLW5VKSzVyPUCuNFk1PjJizszN	NHzkPJhUSU6JRWK=
NB5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEm2NlUh\|ryP	MV;TRW5ITVJ?
A704	NFrwZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;NN5BKUUN3ME2wMlA6PzRzIN88US=>	MXPTRW5ITVJ?
SF268	NYDZZ4F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMEm4NlUh\|ryP	MXnTRW5ITVJ?
UACC-257	NYn5TnZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMEm4N\|Mh\|ryP	M3OxUnNCVkeHUh?=
L-428	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vndmlEPTB;MD6xNFMzKM7:TR?=	NIe4WXJUSU6JRWK=
ST486	NEfzb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMUC2NFYh\|ryP	NF;KWoRUSU6JRWK=
SK-MM-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXwRXZWUUN3ME2wMlExPzB7IN88US=>	NYDrXpprW0GQR1XS
COR-L279	M3uyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXm4[GRqUUN3ME2wMlExQDN{IN88US=>	Mof5V2FPT0WU
JiyoyeP-2003	NIHFUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTXTWM2OD1yLkGwPFQ{KM7:TR?=	MlrBV2FPT0WU
GT3TKB	NIr2fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\PR2lEPTB;MD6xNFkyQCEQvF2=	MVHTRW5ITVJ?
HCE-T	M3K3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPKNGhKSzVyPUCuNVA6PCEQvF2=	M3\oW3NCVkeHUh?=
SBC-1	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TDOmlEPTB;MD6xNVEyQSEQvF2=	NYraenNtW0GQR1XS
KNS-81-FD	M2myRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrOTWM2OD1yLkGxNlc{KM7:TR?=	MVPTRW5ITVJ?
NCI-H2126	NUXSd411T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMUGzPVQh\|ryP	NGPz[WtUSU6JRWK=
EM-2	NXH0d41vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MornTWM2OD1yLkGxOVI6KM7:TR?=	MV;TRW5ITVJ?
JAR	NH\UPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMUG1PVgh\|ryP	NXfVXVlnW0GQR1XS
NB17	NVG5TI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzVcZVoUUN3ME2wMlEyPjV{IN88US=>	NHPFNlFUSU6JRWK=
LB647-SCLC	NUnyR2J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUWxdGNWUUN3ME2wMlEyPzB3IN88US=>	NF;WOJZUSU6JRWK=
CAL-148	NXrJ[oxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMUG4JO69VQ>?	NVPPR4p{W0GQR1XS
K052	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLXSIJPUUN3ME2wMlEyQDVzIN88US=>	NWjXSo52W0GQR1XS
KARPAS-299	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fQNWlEPTB;MD6xNlI{OyEQvF2=	NVTsd\|g3W0GQR1XS
KARPAS-422	NFTNbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMUK0N\|Ih\|ryP	NVXo[lZiW0GQR1XS
LOXIMVI	Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlL3TWM2OD1yLkGyOVE2KM7:TR?=	M{TPbnNCVkeHUh?=
SCC-3	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnOUZlxUUN3ME2wMlEzQDVzIN88US=>	M4jubnNCVkeHUh?=
LU-139	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknmTWM2OD1yLkGyPVc2KM7:TR?=	M4juWXNCVkeHUh?=
COLO-320-HSR	NF7rZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMUOwPFYh\|ryP	MVXTRW5ITVJ?
ONS-76	NXXCTnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:zTWM2OD1yLkGzNVMh\|ryP	NGfMUolUSU6JRWK=
U-266	M37NXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMUOyOFUh\|ryP	NFvxdnpUSU6JRWK=
HH	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTDR3FYUUN3ME2wMlE{PTN3IN88US=>	MonrV2FPT0WU
BB49-HNC	M1HNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPkTWM2OD1yLkGzOVg4KM7:TR?=	M4DxNHNCVkeHUh?=
NCI-SNU-5	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z3V2lEPTB;MD6xN\|U6PiEQvF2=	M{P6[nNCVkeHUh?=
C2BBe1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2m1NWlEPTB;MD6xN\|c1PiEQvF2=	NU\ubVZCW0GQR1XS
ML-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;nXmlEPTB;MD6xN\|k2OyEQvF2=	MVzTRW5ITVJ?
SCH	NHrqZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vITmlEPTB;MD6xN\|k4PCEQvF2=	NFrBPJNUSU6JRWK=
NCI-H82	M2HQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jmV2lEPTB;MD6xOFExPCEQvF2=	M1S0e3NCVkeHUh?=
MDA-MB-134-VI	NHfwWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moe3TWM2OD1yLkG0NlUzKM7:TR?=	NVLRVoQ2W0GQR1XS
SK-N-DZ	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMUS3NVkh\|ryP	Mo[xV2FPT0WU
HL-60	M1S4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMUS5NkDPxE1?	M1LlNnNCVkeHUh?=
LB373-MEL-D	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInZVWtKSzVyPUCuNVU2OzlizszN	NW\nfGdpW0GQR1XS
LB831-BLC	NGK2R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPEWmFKSzVyPUCuNVYxPzZizszN	NYPENJlsW0GQR1XS
SK-NEP-1	NVP2TXFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjhcnNlUUN3ME2wMlE3OTBzIN88US=>	NV;3dXJDW0GQR1XS
IMR-5	M1HqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXmTWM2OD1yLkG2OFg{KM7:TR?=	NF6yeohUSU6JRWK=
Calu-6	M2qy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLOfWlmUUN3ME2wMlE3PTN5IN88US=>	M3LGbHNCVkeHUh?=
NCI-H1882	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;2UGhKSzVyPUCuNVY4OjhizszN	NWP2XZB{W0GQR1XS
NCI-H446	NGm2U\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMU[4PVEh\|ryP	Ml;4V2FPT0WU
GI-ME-N	NFfSTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HKcmlEPTB;MD6xPFAzKM7:TR?=	MV\TRW5ITVJ?
MPP-89	NYfJUmVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3pTWM2OD1yLkG4NVIyKM7:TR?=	MX;TRW5ITVJ?
CGTH-W-1	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjFTWM2OD1yLkG4OFM3KM7:TR?=	M{j4fHNCVkeHUh?=
MEG-01	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHIVohkUUN3ME2wMlE5PjJ6IN88US=>	MlfyV2FPT0WU
NCI-H748	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33i[GlEPTB;MD6xPFkyOSEQvF2=	M1vjbnNCVkeHUh?=
COLO-829	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfY[YI3UUN3ME2wMlIxPjd\|IN88US=>	NFy4cpRUSU6JRWK=
GOTO	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rSN2lEPTB;MD6yNFc{KM7:TR?=	NYrmXnJGW0GQR1XS
EW-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\jNWlEPTB;MD6yNVcyQCEQvF2=	NISxV\|RUSU6JRWK=
KY821	NX;kN3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYO3T3dJUUN3ME2wMlIzODR3IN88US=>	M4Kx[3NCVkeHUh?=
CTB-1	M2XFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMkKyNlgh\|ryP	NHX5SVVUSU6JRWK=
TALL-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG4TWM2OD1yLkKyPVIyKM7:TR?=	M3zpZnNCVkeHUh?=
NCI-H209	NYrXXYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LPRWlEPTB;MD6yNlk3OiEQvF2=	NV7tbXVIW0GQR1XS
IST-MES1	NXfGfYZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrzeYJKSzVyPUCuNlM2OSEQvF2=	MWTTRW5ITVJ?
DMS-114	M1\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMkO5PVMh\|ryP	M1P5VnNCVkeHUh?=
SNU-C2B	NYPjbHlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7ITWM2OD1yLkK0N\|E3KM7:TR?=	NFHQW5VUSU6JRWK=
DG-75	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMk[xPVUh\|ryP	NVrM[pIyW0GQR1XS
D-336MG	M1nNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMk[1OVch\|ryP	NGDDZ3hUSU6JRWK=
KMOE-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nUPGlEPTB;MD6yO\|U{QCEQvF2=	NUfISoU{W0GQR1XS
NB1	NHjhO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMke5NlYh\|ryP	NXi0dZFWW0GQR1XS
RH-1	M4DSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jseGlEPTB;MD6yO\|k5QSEQvF2=	NXi4V\|g{W0GQR1XS
TE-1	MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMki0O\|kh\|ryP	M1Lsb3NCVkeHUh?=
RPMI-6666	NWe2Rox1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLsTWM2OD1yLkK4PFQh\|ryP	MkC1V2FPT0WU
TE-9	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTYTWM2OD1yLkK4PVg2KM7:TR?=	M{X0fXNCVkeHUh?=
BT-474	M2\UTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\OWlhKSzVyPUCuNlk{OzRizszN	MVLTRW5ITVJ?
COLO-668	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMkm0Nlkh\|ryP	M17ZbnNCVkeHUh?=
NCI-H1581	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDOUZJKSzVyPUCuNlk3QDlizszN	NYGxcnQ5W0GQR1XS
MN-60	NUPERYZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMkm5NFUh\|ryP	NFXsT3lUSU6JRWK=
L-540	NELGc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwM{CwPFEh\|ryP	M2fRbHNCVkeHUh?=
MOLT-13	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwM{CxPFMh\|ryP	NVj5SGFCW0GQR1XS
NCI-SNU-16	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULWTXZsUUN3ME2wMlMxOjB3IN88US=>	NX7ze3plW0GQR1XS
NCI-H64	NXXIS5FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjo[2ZKSzVyPUCuN\|A{OzFizszN	MoLFV2FPT0WU
CP66-MEL	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwM{G0NVUh\|ryP	MUfTRW5ITVJ?
NB69	NXnHZ4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr2UVA6UUN3ME2wMlMzOTh6IN88US=>	MUDTRW5ITVJ?
NCI-H2196	M3vZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jSNmlEPTB;MD6zN\|A{PiEQvF2=	NFOybHFUSU6JRWK=
MHH-CALL-2	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIe1NVdKSzVyPUCuN\|M1PjhizszN	MVLTRW5ITVJ?
HCC2157	NV3vO2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnOcnJzUUN3ME2wMlM{QTV2IN88US=>	MmW4V2FPT0WU
LS-1034	Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLZTWM2OD1yLkO2N\|g5KM7:TR?=	MmezV2FPT0WU
BOKU	NVnEWZl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnaTWM2OD1yLkO3NVk6KM7:TR?=	NH;UTXFUSU6JRWK=
GDM-1	NUP0Zo01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLtWGdKSzVyPUCuN\|czOzRizszN	M1\xfHNCVkeHUh?=
TGW	MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jDS2lEPTB;MD6zO\|Q2OyEQvF2=	NYqw[49MW0GQR1XS
SNU-C1	NX7tVmJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwM{iyNVUh\|ryP	M4q4d3NCVkeHUh?=
LS-513	M1X3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHaZWNUUUN3ME2wMlM6ODdzIN88US=>	MVjTRW5ITVJ?
NOMO-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPqPIM4UUN3ME2wMlM6QTdzIN88US=>	MmC4V2FPT0WU
MS-1	NHHzS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\ZUZhKSzVyPUCuOFAyPzdizszN	M3LXXnNCVkeHUh?=
EKVX	NWXGXVloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LBPGlEPTB;MD60OFQ3OSEQvF2=	NXjmUHB3W0GQR1XS
SK-MEL-2	NVm2dVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknxTWM2OD1yLkS2OEDPxE1?	NWXBd3pNW0GQR1XS
HCC1187	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nvOmlEPTB;MD60Olc3QCEQvF2=	MYXTRW5ITVJ?
HCC2218	NVPMRnl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXLdJFKSzVyPUCuOFczOjdizszN	MknjV2FPT0WU
NCI-H187	M1L0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\FUJRKSzVyPUCuOFc5PCEQvF2=	MWfTRW5ITVJ?
DB	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M12wSGlEPTB;MD61NFA2PSEQvF2=	Mnq1V2FPT0WU
NCI-H69	NVvER3VZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPsSVVKSzVyPUCuOVAzPDdizszN	NGHTXXhUSU6JRWK=
NCI-H1694	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTyTWM2OD1yLkWwOlk4KM7:TR?=	NIrsUVFUSU6JRWK=
CA46	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGH6NYpKSzVyPUCuOVA6OTdizszN	NYLYXZA{W0GQR1XS
EHEB	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWH0N3M4UUN3ME2wMlUyOTl\|IN88US=>	NInHWo9USU6JRWK=
NCCIT	NEHJUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonqTWM2OD1yLkW0N\|IyKM7:TR?=	MYnTRW5ITVJ?
NCI-H720	NXizUZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwNUS5OlIh\|ryP	NIHv[XZUSU6JRWK=
LU-134-A	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjEblFkUUN3ME2wMlU2Ojl4IN88US=>	M{XxfnNCVkeHUh?=
MC-CAR	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfoZZBSUUN3ME2wMlU2PDNzIN88US=>	NV62UWdWW0GQR1XS
NEC8	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33CUmlEPTB;MD61OlE4OiEQvF2=	NVm4fnlbW0GQR1XS
NCI-H524	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzXfoFKSzVyPUCuOVg4PDhizszN	M3nsb3NCVkeHUh?=
NCI-H1963	M1nBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rhXmlEPTB;MD62NlU5KM7:TR?=	M3LqeXNCVkeHUh?=
SU-DHL-1	M1HBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7UcYNKSzVyPUCuOlQ2OjZizszN	NVjyN49YW0GQR1XS
NCI-H1522	NEPiWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TSe2lEPTB;MD62OFg5OyEQvF2=	NXfoR2h{W0GQR1XS
NCI-H1155	NWnW[ZRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHRTWM2OD1yLk[1N\|Uh\|ryP	MlzEV2FPT0WU
D-263MG	M2jtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDo[G1IUUN3ME2wMlY3OTBzIN88US=>	NFS5ZVFUSU6JRWK=
TE-6	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwNkixNFQh\|ryP	NVy2eFJFW0GQR1XS
NCI-H1417	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwNkm3NVEh\|ryP	NVrBW4hqW0GQR1XS
NCI-H510A	NGn6SWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvTdmhrUUN3ME2wMlc4OjN4IN88US=>	Mof1V2FPT0WU
KARPAS-45	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv3UHFKSzVyPUCuO\|gzOzVizszN	NH20em9USU6JRWK=
IST-SL1	NFGzbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjnTWM2OD1yLki1PFI2KM7:TR?=	Mn\JV2FPT0WU
COLO-824	NIPPWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGC2fHBKSzVyPUCuPFc5OzVizszN	MmjZV2FPT0WU
NCI-H526	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XZVGlEPTB;MD65NFk2QCEQvF2=	M3HKN3NCVkeHUh?=
NCI-H719	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPwTWM2OD1yLkm2OlU4KM7:TR?=	M2qyS3NCVkeHUh?=
SF539	NGjOR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHaTWM2OD1yLkm4N\|k3KM7:TR?=	NXXz[YJPW0GQR1XS
NKM-1	NFrK[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nCeGlEPTB;MD65PFY3OyEQvF2=	MV\TRW5ITVJ?
A253	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXm3b3VTUUN3ME2wMlk5QDh3IN88US=>	MVfTRW5ITVJ?
TE-441-T	NIO0fHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfmXppKSzVyPUGuNFQ{PSEQvF2=	Mn\mV2FPT0WU
COR-L88	NYLGNmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHzb5dzUUN3ME2xMlEyOzV2IN88US=>	MYjTRW5ITVJ?
CPC-N	NF\nWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlm3TWM2OD1zLkG1PFg5KM7:TR?=	MnuyV2FPT0WU
NCI-H2107	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnBW5ZKSzVyPUGuNVczPjFizszN	NYrWUIJ7W0GQR1XS
ECC4	NXLudo5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn65TWM2OD1zLkG4Olk{KM7:TR?=	M1;jfnNCVkeHUh?=
NCI-H2141	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvrXXFKSzVyPUGuNVkzQTlizszN	MnTxV2FPT0WU
NCI-H1770	M32wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHRXotKSzVyPUGuN\|I6OjhizszN	MlvXV2FPT0WU
NCI-SNU-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEOwdpFKSzVyPUGuN\|MxPCEQvF2=	MmjnV2FPT0WU
LU-165	NV7ScmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGni[nBKSzVyPUGuOFU1PjdizszN	NFHKb3FUSU6JRWK=
Raji	NXXucoFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fNdGlEPTB;MT60O\|I2QSEQvF2=	NVu3bXNNW0GQR1XS
EW-24	NXPDNoNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz2UGZEUUN3ME2xMlU1PjF7IN88US=>	M1S4bXNCVkeHUh?=
KP-N-RT-BM-1	NGLyXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPm[5VoUUN3ME2xMlU3PTVzIN88US=>	MmTRV2FPT0WU
SK-MEL-1	M4fOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzyTWM2OD1zLk[0PFc4KM7:TR?=	NV\PVWNIW0GQR1XS
SCLC-21H	NHKwd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nzTGlEPTB;MT62OlY2OSEQvF2=	M4PiW3NCVkeHUh?=
SIMA	NUfpTnYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL5SlJjUUN3ME2xMlY5OjN\|IN88US=>	M4LU[HNCVkeHUh?=
NCI-H1304	Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn6yTWM2OD1zLkewO\|Y2KM7:TR?=	NVjG[lVlW0GQR1XS
REH	NVLoXY0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXLZVVKSzVyPUGuO\|ExPzhizszN	MVXTRW5ITVJ?
KP-N-YS	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\pS2lEPTB;MT65N\|U2OSEQvF2=	MXXTRW5ITVJ?
DMS-153	NGW0WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXxTWM2OD1zLkm3OVkh\|ryP	MWTTRW5ITVJ?
NB10	M2fwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTJwMkC4O\|gh\|ryP	MWHTRW5ITVJ?
NCI-H345	NUTNfVk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlflTWM2OD1{Lk[xPVA2KM7:TR?=	NVW3bXNyW0GQR1XS
SK-N-FI	M{PYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rsO2lEPTB;Mj63OVM5OSEQvF2=	NX24bm5[W0GQR1XS
NCI-H1092	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXNTWM2OD1{Lkm1N\|k1KM7:TR?=	NIq2ZllUSU6JRWK=
KM-H2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULFXIJ{UUN3ME2zMlY2Ozl4IN88US=>	M3W2O3NCVkeHUh?=
KG-1	NWnpcYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX2yT2pGUUN3ME2zMlcyPjh6IN88US=>	M3jyWXNCVkeHUh?=
D-283MED	NEjTTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTNwN{W4O{DPxE1?	MXXTRW5ITVJ?
LU-65	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7aTWM2OD12LkGxOFg2KM7:TR?=	MoXzV2FPT0WU
MSTO-211H	M2TiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;kRnpKSzVyPUSuNVg5QThizszN	M2KwWnNCVkeHUh?=
NCI-H2081	M4nENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzVV\|hDUUN3ME20MlI6OTd2IN88US=>	NWGxOWdrW0GQR1XS
D-247MG	M{jLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3yfG1[UUN3ME20MlQ{OTlzIN88US=>	Mo\0V2FPT0WU
P31-FUJ	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTUdXA{UUN3ME20MlQ2ODF7IN88US=>	NFvMcGNUSU6JRWK=
DMS-79	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXUTWM2OD12LkmzNVg{KM7:TR?=	M4\jT3NCVkeHUh?=
KASUMI-1	NXXzNlB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonITWM2OD12Lkm3OVA6KM7:TR?=	MnP5V2FPT0WU
JVM-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHn4[XRKSzVyPUWuNlUxOTRizszN	NHX1NVlUSU6JRWK=
LAN-6	M4K0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLnWFc5UUN3ME21MlUyPzN4IN88US=>	MXPTRW5ITVJ?
DJM-1	NIrvVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILLbZpKSzVyPUWuOVYxOjlizszN	MVLTRW5ITVJ?
JVM-2	NXzNWmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj3R3dVUUN3ME21MlY4ODl{IN88US=>	M{XoWnNCVkeHUh?=
U-87-MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTVwOEm5OlQh\|ryP	M3ztN3NCVkeHUh?=
SHP-77	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTVS4YyUUN3ME21Mlk1QTJ6IN88US=>	NIHCbFZUSU6JRWK=
RPMI-8866	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1q1VWlEPTB;Nj6yO\|AyOyEQvF2=	MVnTRW5ITVJ?
ES7	NYHTW2lPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkX3TWM2OD14LkO5PVI1KM7:TR?=	NV7vfY0xW0GQR1XS
WSU-NHL	M{OzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHuTWM2OD14LkWxOlA6KM7:TR?=	NGHPbHhUSU6JRWK=
CAS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLyTWM2OD15LkC5O\|Q6KM7:TR?=	NHHtNWlUSU6JRWK=
MHH-NB-11	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\ZXWlEPTB;OD6yN\|E2OiEQvF2=	MlrEV2FPT0WU
ES5	M2HqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTlwNUKyPFYh\|ryP	MU\TRW5ITVJ?
HDLM-2	NVvqToU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\RTWM2OD17Lkm1PVAzKM7:TR?=	NGHUXJdUSU6JRWK=
NCI-H2171	M3voVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\hXml7UUN3ME2xNE42QTJ5IN88US=>	MYTTRW5ITVJ?
LNCaP-Clone-FGC	NH;sV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHCbm9KSzVyPUGxMlM4OThizszN	NF\tR2VUSU6JRWK=
NCI-H1395	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTF{LkK2PVkh\|ryP	NHvtXXdUSU6JRWK=
NCI-H1436	NI\jRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfYTWM2OD1zMz6zNVk2KM7:TR?=	MWnTRW5ITVJ?
RCC10RGB	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4f5d2lEPTB;MUOuN\|IzOSEQvF2=	M3vQSnNCVkeHUh?=
SW684	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\uWoxKSzVyPUGzMlk4QTdizszN	MmSzV2FPT0WU
NCI-H1650	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHYXYhKSzVyPUG1MlA1PDdizszN	MWrTRW5ITVJ?
EW-13	NFXieYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33qR2lEPTB;MUWuNlAzOSEQvF2=	MYnTRW5ITVJ?
EC-GI-10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTF3Lki2OFQh\|ryP	M1S3U3NCVkeHUh?=
CHP-126	NVOwU4lIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rDUWlEPTB;MUeuNVkyQCEQvF2=	NVW0PZFNW0GQR1XS
NCI-H226	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTF6LkC0NFMh\|ryP	MX7TRW5ITVJ?
NCI-H1838	M4nGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DieWlEPTB;MkCuNVg1QCEQvF2=	NEfyfmFUSU6JRWK=
EW-11	NVnEdXFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmT6TWM2OD1{ND6yO\|E5KM7:TR?=	M4\MS3NCVkeHUh?=
EB2	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHr4XFRKSzVyPUOxMlU{OThizszN	MoXIV2FPT0WU
D-502MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWP6RoVIUUN3ME20N{46OjJ7IN88US=>	NW\qeHh{W0GQR1XS
U-698-M	NGH2XJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfkZ4h{UUN3ME20PE45PjdzIN88US=>	NITi[HhUSU6JRWK=
ES3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnOxTWM2OD12OT6zPFk{KM7:TR?=	MlzSV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	+ Expand Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

+ Expand

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1